Medical devices, healthcare technology and the business of care
PMA approval · P990040

TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM

Cerenovus, Inc. · Decision date Sep 25, 2000

FDA DECISIONP990040

What did the FDA approve?

FDA records P990040 as an original PMA application. The recorded decision is approval, dated Sep 25, 2000.

FDA approval order statement

APPROVAL FOR THE TRUFILL(R) N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM. THE DEVICE IS INDICATED FOR THE EMBOLIZATION OF CEREBRAL ARTERIOVENOUS MALFORMATIONS (AVMS) WHEN PRESURGICAL DEVASCULARIZATION IS DESIRED.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Sep 25, 2000

FDA source record

Regulatory record facts

Identifier
P990040
Regulatory pathway
Premarket approval application
Product code
KGG
Decision code
APPR
Decision date
Sep 25, 2000
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: tissue adhesive for use in embolization of brain arteriovenous malformations.

Product code
KGG
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P990040 received

    Application receipt date recorded by FDA.

  2. P990040 · FDA decision

    APPR

  3. P990040/S037 · Related supplement

    TRUFILL n-BCA Liquid Embolic System

Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990040

Product / regulatory recordCompanyPathwayDecision dateSource
Cerenovus, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cerenovus, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6303 Waterford District Dr., Suite 315, Miami, FL, 33126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records